Glucagon-like peptide-1 (GLP-1) was first identified as an insulinotropic peptide during research aimed at understanding the incretin effect. Its discovery has led to significant advancements in diabetes and obesity treatment. GLP-1 plays a crucial role in regulating glucose metabolism and has been shown to inhibit glucagon secretion, gastrointestinal motility, and appetite.
In patients with type 2 diabetes mellitus (T2DM), GLP-1 has demonstrated the ability to improve glycemic control and enhance beta cell function. The short half-life of GLP-1 in circulation, due to renal clearance and enzymatic degradation, necessitated the development of stable analogs. These analogs have been designed for long-term treatment and have proven effective in managing blood sugar levels and promoting weight loss.
Clinical trials have shown that GLP-1 receptor agonists, particularly those suitable for weekly administration, significantly improve glycemic control in T2DM patients. Additionally, these agonists have been associated with protective effects against major cardiovascular events, as well as providing renoprotection and neuroprotection.
Observational studies have suggested that GLP-1 receptor agonists may also offer protection against psychiatric disorders and dementia, indicating a broader therapeutic potential beyond metabolic health. The findings suggest that GLP-1 receptor agonists could be instrumental in addressing the obesity-associated cardiovascular-kidney-metabolic syndrome, which affects millions globally.
What this study does not show
This review does not provide direct evidence from clinical trials regarding the efficacy of GLP-1 receptor agonists in preventing psychiatric illnesses or dementia.
Evidence scorecard
- Analytic validity: Established
- Clinical validity: Partial
- Clinical utility: Partial
The evidence is based on a review of existing literature and clinical findings related to GLP-1 and its analogs.